Time-resolved fluorescence based direct two-site apoA-I immunoassays and their clinical application in patients with suspected obstructive coronary artery disease.

Front Cardiovasc Med · 2022 · PMC9614376 · PMID 36312264

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

borderline significanceP = 0.05actually significant

However, in the whole cohort, the level of apoA-I 110−525 was similar in patients with and without coronary atherosclerosis ( P = 0.29), since apoA-I 110−525 tended to be lower in the presence of atherosclerosis with a borderline significance ( P = 0.05) among patients taking LLM.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.